This open-label pilot study focuses on the peer intervention program called CArdiovascular Risk assEssment for RA (CARE RA), which provides information about the association between cardiovascular disease (CVD) and rheumatoid arthritis (RA) to patients. The study is conducted by evaluating whether patients receive a CVD risk assessment more frequently if they complete the CARE RA curriculum with a peer coach versus individually.
This study aims to analyze rheumatologist and patient mental models in order to inform interventions for rheumatoid arthritis that adopt the “target to treat” (TTT) approach, which adjusts treatment to achieve a target based on disease status and activity.
Methotrexate is a commonly prescribed drug for patients diagnosed with rheumatoid arthritis (RA). Though it can positively impact disease activity, some patients experience side effects and intolerance. Salt et al. developed a scale to measure methotrexate intolerance for use in adult rheumatoid arthritis (RA) patients with an additional objective to describe its psychometric properties.
This study aims to quantify methotrexate (MTX)-associated side effects in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients. In the ArthritisPower app and registry, a self-controlled case series study design with electronic patient-reported outcome measures (e-PROMs) was used.
This virtual, longitudinal study explores the different patient-reported outcomes (PROs) that patients with rheumatic and musculoskeletal diseases consider important for their disease management.
Using data from a community practice-based rheumatologist network, this article explores the impact of the COVID-19 pandemic on rheumatology care and the use of telehealth.
Researchers explore whether an online video intervention discussing appropriate treatment escalation improves willingness to change treatment in people living with rheumatoid arthritis (RA).
Researchers surveyed women over 40 who have had at least one pregnancy after their inflammatory arthritis diagnosis. They found that there is a need for better family planning care for women with childbearing potential.
This study analyzed PROMIS Fatigue SF scores in RA patients across the range of disease activity in order to evaluate score validity.
In Arthritis Care & Research, Yun et al. report using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) instruments in substitution for lengthier Patient-Reported Outcomes instruments such as the Routine Assessment of Patient Index Data 3 (RAPID3). 6,154 eligible patients contributed 11,275 observations using 4 PROMIS computer-adaptive testing instruments and the RAPID3. There was excellent agreement between the observed RAPID3 and predicted RAPID3 scores estimated using several PROMIS instruments. PROMIS may be used in place of RAPID3 and other patient global assessment components.
Research for patients, by patients.
A Creakyjoints initiative.
PatientSpot registry infrastructure was funded through a Patient-Centered Outcomes Research Institute Award (PCORI Contract Number PPRN-1306-04811). PatientSpot (formerly known as Arthritis Power) was jointly developed by the nonprofit Global Healthy Living Foundation (GHLF), its associated CreakyJoints arthritis patient community, and rheumatology researchers at the University of Alabama at Birmingham (UAB). We reserve the right to change and add sponsors and partner organizations and we also reserve the right to change placement of text on the page. Created by CreakyJoints® patient community in collaboration with patient advocates at Global Healthy Living Foundation (GHLF) and researchers at the University of Alabama at Birmingham (UAB), Arthritis Power (now PatientSpot)’s past participation in PCORnet®, the National Patient-Centered Clinical Research Network, was supported through multiyear, multimillion-dollar Patient-Centered Outcomes Research Institute funding awards [PPRN-1306-04811]. Global Healthy Living Foundation (GHLF), the parent organization of PatientSpot, receives grants, sponsorships and contracts from pharmaceutical manufacturers and private foundations. A full list of GHLF funders is publicly available here: https://www.ghlf.org/our-partners.
POWERED BY
© Copyright 2024 PatientSpot
